# T-E Meds

Source: https://onco.cc/companies/t-e-meds/  
OnCo record `t-e-meds` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

T-E Meds is a Taipei company that builds antibody-drug conjugates, antibodies that carry drugs to cancer cells, using linkers that hold several drug molecules at once. Its HER2 medicine TE-1182 carries two different cell-killing drugs and has orphan drug status for gastric cancer.

## Summary

T-E Meds Inc., in Nangang District, Taipei, was established in 2022 as the second subsidiary of T-E Pharma Holding, according to the company. It uses a multi-arm linker platform to make drug bundles that are site-specifically conjugated to antibodies, producing homogeneous high drug-to-antibody-ratio antibody-drug conjugates and antibody-radionuclide conjugates; it says its candidates, for multiple myeloma, pancreatic cancer and HER2-related cancers, are in preclinical development. Its HER2 candidate TE-1182, made with CHO Pharma, carries both MMAF and exatecan on trastuzumab. On 6 October 2026 the FDA granted orphan drug designation for gastric cancer to a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate sponsored by T-E Meds.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: T-E Meds, Inc.; T-E Meds Inc.
- HQ: Taipei
- Type: biotech
- Website: https://www.temeds.com/

## Notes

- The company's anti-CD38 lenalidomide conjugate for multiple myeloma is not recorded as a product here. Read on 4 November 2026.

## Sources

- Official website: https://www.temeds.com/
- TE-1182: https://www.temeds.com/te-1182/
- FDA orphan designation, gastric cancer, 6 October 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145626

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [TE-1182](https://onco.cc/drugs/te-1182/)

---
JSON: https://onco.cc/api/v1/entities/t-e-meds.json